CURISPHAR
ActiveSummary
The computed 12-month bankruptcy probability of CURISPHAR is 2.1% (moderate). The 2025 annual accounts show equity of €26,354 and a net result of €202,193. Equity has been growing by about 32% per year since 2019. Its solvency ranks better than 15% of 2,812 sector peers (NACE 82, financial year 2025). The company has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Official details
Source: KBO- Status
- Active since 04-02-2019 Normal situation
- Activity
- Other business support services NACE 82990
- Establishment unit
- 2.285.033.948 8540 Deerlijk, since 04-02-2019
- Financial year end
- 31 December
- Peppol
- Reachable since 18-09-2025
Board and ownership
- Charlotte VANDENBUSSCHEDirector · since 04-02-2019
- Tim WINDELSDirector · since 14-01-2020
- Holdings
- Shares in 1 company Apotheek Vichte
Financial position
- Bankruptcy probabilitywithin 12 months
- 2.1%
- Gross margin
- €292,735
- ▲ 28.0%
- Turnover
- ≈ €440,000
- estimated
- Profit
- €202,193
- ▲ 36.6%
- Equity
- €26,354
- ▼ 94.5%
- Total assets
- €1.4m
- ▲ 1.2%
Score breakdownraises risk2 changes of registered office in 24 monthsEquity €26,354 (1.9% of total assets)lowers riskSize: total assets €1.4mSector: Office administrative, office support and other business support activities (NACE 82)Show the evidence
Checked score
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 82, micro). It does better than 15% of them on solvency, 16% on liquidity, 61% on profitability and 5% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 27 days before the deadline. In the sector (NACE 82), the median for financial year 2024 was 7 days before the deadline, and 35% of those companies filed late.
Searched, nothing found (2)
Key points
- Caution: Equity fell in 2025from €482,161 to €26,354 ▼ 94.5% View
- Caution: Lower solvency than 85% of companies in office administrative supportsector median 41.4% · 2,812 companies 1.9% View
- Positive: Always filed on timeaccounts within the deadline every year 7 years View
- Positive: 7 profitable years in a rowprofit 2025: €202,193 7 years View
Recent changes
- · Gazette deed Registered office moved within DeerlijkPermanent representative: Gunther Kerkhof
- · Gazette deed Registered office moved within Deerlijk
- · Gazette deed Registered office moved from Marke to Deerlijk
Comparable companies
These companies have the same main activity as CURISPHAR: other business support services (NACE 82990). They are comparable in size and age: total assets between €851,000 and €2.2m, founded between 2016 and 2022.
| Company | Total assets | Gross margin |
|---|---|---|
| CURISPHAR Deerlijk | €1.4m | €0.3m |
| Strybol Wout Pharma Brugge | €2.2m | €0.2m |
| BARIZZA Koksijde | €0.9m | €0.3m |
| WAB Olen | €1.9m | €0.3m |
| Pierre-Baudoin Holding Namur | €1.1m | €0.2m |
| EMM HASSELT Lanaken | €1.8m | €0.2m |
| CR Pharma Harelbeke | €2.2m | €0.3m |
Key facts about CURISPHAR
- What is the company number of CURISPHAR?
- The company number of CURISPHAR is 0719.758.212. The VAT number is the same number with BE in front: BE 0719.758.212.
- Where is CURISPHAR based?
- The registered office is at Heestertstraat 39, 8540 Deerlijk.Company details
- What does CURISPHAR do?
- According to the KBO register, the main activity is other business support services (NACE 82990).
- What is the legal form of CURISPHAR?
- The legal form of CURISPHAR is Private limited company (BV).
- When was CURISPHAR founded?
- CURISPHAR was founded on 04-02-2019.
- Is CURISPHAR still active?
- Yes, CURISPHAR is an active enterprise in the KBO register.
- What is the turnover of CURISPHAR?
- The turnover in financial year 2025 is ≈ €440,000. This figure is estimated from the gross margin of €292,735 and 33 comparable companies (NACE 82990). It probably lies between €360,000 and €620,000.Financials
- Is CURISPHAR profitable?
- In financial year 2025, CURISPHAR made a profit of €202,193.
- Where can I find the annual accounts of CURISPHAR?
- CURISPHAR filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of CURISPHAR due?
- CURISPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.